Interleukin-23: The Common Link Between the Joint, the Gut, and the Skin?

Abstract

Prof McGonagle introduced the symposium and briefly described the aims of the meeting. Dr Behrens first discussed how findings from relevant psoriasis and psoriatic arthritis (PsA) registries can be applied to improve daily practice, and reflected on the real-life effectiveness of biologic therapies in the treatment of PsA. Prof McGonagle then followed with a discussion describing the key immunological pathways involved in psoriasis and PsA, evaluating the key similarities and differences in tissue and cytokine pathobiology in both conditions. Prof Danese then concluded the symposium by presenting on the pathophysiology of the interleukin (IL)-23 pathway in inflammatory bowel disease (IBD), reviewing the latest data for IL-23 inhibitors in treating IBD.